{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:17:37Z","timestamp":1788427057867,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.coi.2026.102830","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:17:44Z","timestamp":1785273464000},"page":"102830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin\u2013joint interface in inflammatory diseases: a narrative review"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-8838","authenticated-orcid":false,"given":"Marco","family":"Cattalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Amerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bertolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Gualdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102830_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: population-based cohort study","volume":"150","author":"de Lusignan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2026.102830_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.alit.2023.12.005","article-title":"Unraveling the link between atopic dermatitis and autoimmune diseases in children: insights from a large-scale cohort study with 15-year follow-up and shared gene ontology analysis","volume":"73","author":"Ahn","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.coi.2026.102830_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.coi.2026.102830_sbref4","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.5826\/dpc.1503a5064","article-title":"Atopic dermatitis and autoimmune connective tissue diseases: systematic review and meta-analysis","volume":"15","author":"Naassan","year":"2025","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"10.1016\/j.coi.2026.102830_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2020.05.091","article-title":"Atopic dermatitis is associated with dermatitis herpetiformis and celiac disease in children","volume":"141","author":"Kauppi","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamadermatol.2023.2875","article-title":"Risk of inflammatory bowel disease in patients with atopic dermatitis","volume":"159","author":"Chiesa Fuxench","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaad.2022.12.025","article-title":"Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: a Finnish nationwide registry study","volume":"88","author":"Keskitalo","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib8","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1177\/0961203314543920","article-title":"Increased incidence of juvenile onset systemic lupus erythematosus in children with atopic dermatitis","volume":"23","author":"Wei","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102830_sbref9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2022.12.050","article-title":"Proteomic characterization of atopic dermatitis blood from infancy to adulthood","volume":"88","author":"Del Duca","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2026.102830_sbref10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13601-020-00338-7","article-title":"IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis","volume":"10","author":"Badloe","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.coi.2026.102830_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100513","article-title":"Inborn errors of immunity with atopic phenotypes: a practical guide for allergists","volume":"14","author":"Castagnoli","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.coi.2026.102830_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ced\/llad390","article-title":"Dupilumab associated inflammatory arthritis: a literature review","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib13","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.884727","article-title":"New insights on juvenile psoriatic arthritis","volume":"10","author":"Brunello","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.coi.2026.102830_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/jcm12010367","article-title":"Juvenile psoriatic arthritis: myth or reality? An unending debate","volume":"12","author":"Naddei","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102830_bib16","first-page":"582","article-title":"Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis","volume":"29","author":"Stoll","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102830_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2026.102830_bib19","doi-asserted-by":"crossref","first-page":"11662","DOI":"10.3390\/ijms241411662","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102830_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells.","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2026.102830_sbref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41590-025-02351-z","article-title":"Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints","volume":"27","author":"Raimondo","year":"2026","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2026.102830_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102830_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103711","article-title":"The association between physical trauma and autoimmune articular and dermatological disorders","volume":"24","author":"Muhsen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102830_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000545694","article-title":"Trauma-induced psoriatic arthritis: a deep K\u00f6bner phenomenon","volume":"17","author":"Mima","year":"2025","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002943","article-title":"Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry","volume":"9","author":"Correll","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102830_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/ard.2010.135731","article-title":"Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?","volume":"70","author":"Otten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102830_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102830_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102830_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102830_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102830_bib31","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1016\/S2665-9913(25)00346-7","article-title":"Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab","volume":"8","author":"Ramanan","year":"2026","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","volume":"24","author":"Leu","year":"2022","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.coi.2026.102830_bib34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3899\/jrheum.130977","article-title":"Hidradenitis suppurativa associated with spondyloarthritis: results from a multicenter national prospective study","volume":"41","author":"Richette","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jbspin.2017.09.005","article-title":"Association between hidradenitis suppurativa and spondyloarthritis","volume":"85","author":"Fauconier","year":"2018","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.coi.2026.102830_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.semarthrit.2018.03.010","article-title":"High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: a possible new extra-articular manifestation","volume":"48","author":"Rondags","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102830_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1159\/000514582","article-title":"Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis","volume":"237","author":"Almuhanna","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.coi.2026.102830_bib38","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102830_bib39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of Hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","article-title":"Biologics for hidradenitis suppurativa: evolution of the treatment paradigm","volume":"20","author":"Maronese","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2026.102830_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0025-6196(11)63565-9","article-title":"A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.coi.2026.102830_bib44","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjd.15740","article-title":"PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity","volume":"178","author":"Sonbol","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000509873","article-title":"Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review","volume":"237","author":"Nikolakis","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.coi.2026.102830_bib46","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","article-title":"Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene","volume":"149","author":"Marzano","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib47","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jaad.2014.10.002","article-title":"PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition","volume":"72","author":"Saraceno","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.18003","article-title":"PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens","volume":"181","author":"Gottlieb","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib49","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3899\/jrheum.171007","article-title":"Is SAPHO syndrome linked to PASH syndrome and hidradenitis suppurativa by nicastrin mutation? A case report","volume":"45","author":"Li","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib50","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/jdv.12765","article-title":"Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone","volume":"29","author":"Staub","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2026.102830_bib51","article-title":"Secukinumab leading to rapid improvement in pyogenic arthritis, acne, pyoderma gangrenosum, and hidradenitis suppurativa (PAPASH) syndrome: a case report and review of treatment modalities for PAPASH patients","volume":"2025","author":"Shevtsova","year":"2025","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib52","article-title":"Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections","volume":"6","author":"Crowley","year":"2018","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.coi.2026.102830_bib53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2026.102830_bib54","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102830_bib55","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kew031","article-title":"Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis, pyoderma gangrenosum and severe acne syndrome","volume":"55","author":"Omenetti","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102830_sbref56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.coi.2026.102830_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00124743-200202000-00005","article-title":"A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome","volume":"8","author":"Steinhoff","year":"2002","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.coi.2026.102830_bib58","first-page":"185","article-title":"SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate","volume":"69","author":"de Souza","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.coi.2026.102830_bib59","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.25251\/skin.8.3.12","article-title":"Chronic nonbacterial osteomyelitis, hidradenitis suppurativa, and SAPHO syndrome","volume":"8","author":"Wang","year":"2024","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.coi.2026.102830_bib60","doi-asserted-by":"crossref","first-page":"adv00311","DOI":"10.2340\/00015555-3672","article-title":"Biologic therapy for hidradenitis suppurativa plus conglobate acne associated with SAPHO syndrome: a case report","volume":"100","author":"Briede","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coi.2026.102830_bib61","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102830_bib62","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2026.102830_bib63","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152600107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152600107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:48:39Z","timestamp":1788425319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152600107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"alternative-id":["S095279152600107X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102830","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From rheumatology to dermatology: cytokine signaling pathways as therapeutic targets at the skin\u2013joint interface in inflammatory diseases: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102830"}}